[{"id":"b1c632b9-d134-488c-81f6-ee676f63b778","acronym":"","url":"https://clinicaltrials.gov/study/NCT04047706","created_at":"2021-07-05T17:24:31.071Z","updated_at":"2024-07-02T16:35:42.221Z","phase":"Phase 1","brief_title":"Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT04047706","lead_sponsor":"Northwestern University","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide • linrodostat (BMS-986205)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 02/22/2024","primary_completion_date":" 02/22/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-24"},{"id":"fc0bdf18-40a4-4610-a9b7-d00d8a3ff0a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04007588","created_at":"2021-01-18T19:41:33.084Z","updated_at":"2025-02-25T14:28:28.357Z","phase":"Phase 2","brief_title":"A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma","source_id_and_acronym":"NCT04007588","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • linrodostat (BMS-986205)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/06/2019","start_date":" 09/06/2019","primary_txt":" Primary completion: 12/19/2019","primary_completion_date":" 12/19/2019","study_txt":" Completion: 12/19/2019","study_completion_date":" 12/19/2019","last_update_posted":"2020-02-05"}]